| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
201,954 |
136,324 |
$4.31M |
| J9271 |
Injection, pembrolizumab, 1 mg |
3,152 |
1,981 |
$3.46M |
| 80053 |
Comprehensive metabolic panel |
123,454 |
71,809 |
$2.19M |
| 77386 |
|
12,142 |
1,078 |
$2.09M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
35,893 |
30,972 |
$2.06M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
16,135 |
11,901 |
$1.69M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
33,758 |
7,584 |
$1.41M |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
39,892 |
19,296 |
$1.32M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
33,565 |
16,726 |
$1.14M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
1,188 |
636 |
$1.03M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
19,561 |
11,064 |
$995K |
| 77336 |
|
5,678 |
2,242 |
$976K |
| J9299 |
Injection, nivolumab, 1 mg |
2,607 |
1,382 |
$821K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
15,323 |
12,566 |
$818K |
| 36415 |
Collection of venous blood by venipuncture |
75,472 |
43,463 |
$811K |
| J2505 |
Injection, pegfilgrastim, 6 mg |
2,925 |
1,733 |
$751K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
19,883 |
12,158 |
$744K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
6,237 |
5,049 |
$719K |
| 77412 |
|
4,686 |
543 |
$719K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
6,263 |
5,152 |
$662K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
141,566 |
84,225 |
$645K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
6,772 |
5,574 |
$637K |
| J7050 |
Infusion, normal saline solution, 250 cc |
27,632 |
12,494 |
$628K |
| J9035 |
Injection, bevacizumab, 10 mg |
3,292 |
1,281 |
$605K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
17,704 |
14,524 |
$598K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
1,880 |
1,218 |
$591K |
| G0378 |
Hospital observation service, per hour |
13,563 |
5,265 |
$574K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
11,368 |
9,610 |
$570K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
4,077 |
2,995 |
$568K |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
10,060 |
8,560 |
$541K |
| J9306 |
Injection, pertuzumab, 1 mg |
522 |
339 |
$526K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
11,311 |
6,915 |
$501K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
11,945 |
7,742 |
$494K |
| J1453 |
Injection, fosaprepitant, 1 mg |
8,166 |
4,381 |
$488K |
| J0178 |
Injection, aflibercept, 1 mg |
6,021 |
4,416 |
$474K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
5,934 |
5,172 |
$474K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
8,942 |
7,667 |
$473K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
12,625 |
8,882 |
$434K |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
1,111 |
609 |
$418K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
2,298 |
908 |
$406K |
| 96402 |
|
3,907 |
3,139 |
$403K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
6,851 |
5,193 |
$399K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,416 |
7,151 |
$371K |
| J9312 |
Injection, rituximab, 10 mg |
1,028 |
488 |
$365K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
33,870 |
17,953 |
$361K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,846 |
3,410 |
$335K |
| 31237 |
|
459 |
379 |
$331K |
| 92134 |
|
34,729 |
27,469 |
$320K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
22,689 |
18,078 |
$312K |
| 77300 |
|
1,902 |
1,371 |
$312K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
3,216 |
2,638 |
$305K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
2,145 |
1,760 |
$296K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
5,732 |
3,638 |
$296K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
704 |
466 |
$280K |
| 49083 |
|
1,190 |
500 |
$268K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
6,432 |
5,326 |
$260K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,636 |
2,935 |
$250K |
| 31575 |
|
3,234 |
2,750 |
$241K |
| J0897 |
Injection, denosumab, 1 mg |
3,035 |
2,352 |
$240K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
22,491 |
15,189 |
$225K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
2,243 |
1,082 |
$220K |
| 77385 |
|
1,025 |
86 |
$219K |
| 76536 |
|
4,123 |
3,579 |
$215K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
687 |
615 |
$214K |
| 92557 |
|
4,215 |
3,761 |
$214K |
| P9035 |
Platelets, pheresis, leukocytes reduced, each unit |
1,006 |
221 |
$213K |
| 36430 |
|
4,776 |
2,469 |
$207K |
| 96367 |
|
9,688 |
5,279 |
$205K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,053 |
1,851 |
$195K |
| J2353 |
Injection, octreotide, depot form for intramuscular injection, 1 mg |
504 |
362 |
$191K |
| 31579 |
|
890 |
733 |
$188K |
| Q5101 |
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram |
2,709 |
636 |
$187K |
| 77338 |
|
1,159 |
792 |
$184K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,785 |
2,247 |
$182K |
| 92083 |
|
11,062 |
9,240 |
$181K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
1,582 |
1,223 |
$178K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
971 |
763 |
$172K |
| 83735 |
|
24,918 |
12,536 |
$171K |
| 92250 |
|
11,397 |
9,936 |
$171K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
3,272 |
2,121 |
$165K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
10,248 |
2,903 |
$159K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
7,501 |
6,368 |
$154K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
947 |
777 |
$154K |
| 96417 |
|
8,676 |
4,765 |
$150K |
| 92567 |
|
7,242 |
6,637 |
$146K |
| 76770 |
|
2,941 |
2,491 |
$146K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
18,049 |
9,700 |
$145K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
24,317 |
18,182 |
$143K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,439 |
1,360 |
$143K |
| 95811 |
|
541 |
479 |
$143K |
| 76512 |
|
2,180 |
1,874 |
$142K |
| 36561 |
|
225 |
184 |
$141K |
| 96415 |
|
5,475 |
3,084 |
$139K |
| 96523 |
|
11,275 |
6,021 |
$135K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
8,218 |
6,653 |
$135K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
1,337 |
1,175 |
$129K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
11,129 |
3,891 |
$128K |
| 96401 |
|
4,552 |
1,826 |
$121K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
20,399 |
13,488 |
$119K |
| 71046 |
Radiologic examination, chest; 2 views |
6,708 |
5,615 |
$118K |
| 31231 |
|
1,400 |
1,225 |
$118K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
1,732 |
1,480 |
$118K |
| 10005 |
|
770 |
629 |
$114K |
| 70543 |
|
1,514 |
1,323 |
$112K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
3,049 |
890 |
$111K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
2,010 |
1,716 |
$111K |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
52 |
49 |
$110K |
| 96416 |
|
3,357 |
1,672 |
$108K |
| 71250 |
|
4,173 |
3,420 |
$108K |
| V2632 |
Posterior chamber intraocular lens |
4,473 |
3,427 |
$104K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
4,494 |
1,351 |
$102K |
| 97161 |
|
3,845 |
3,070 |
$97K |
| 67228 |
|
301 |
264 |
$97K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,472 |
1,281 |
$96K |
| 77066 |
Tomosynthesis, mammo |
3,003 |
2,548 |
$93K |
| 92018 |
|
656 |
590 |
$93K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
1,682 |
1,459 |
$92K |
| 66982 |
|
518 |
390 |
$91K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
23,216 |
15,471 |
$89K |
| 74183 |
|
1,328 |
1,120 |
$87K |
| 87070 |
|
4,825 |
3,405 |
$86K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
2,481 |
850 |
$84K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
4,101 |
1,336 |
$83K |
| 76641 |
|
1,345 |
1,200 |
$83K |
| 72197 |
|
1,198 |
1,037 |
$81K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
2,113 |
1,792 |
$81K |
| 83615 |
|
18,848 |
10,780 |
$80K |
| 20610 |
|
1,871 |
1,421 |
$80K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
59 |
38 |
$79K |
| 92626 |
|
538 |
503 |
$77K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
903 |
781 |
$74K |
| 77334 |
|
1,186 |
836 |
$74K |
| 77301 |
|
1,106 |
824 |
$73K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
1,661 |
1,287 |
$71K |
| 86850 |
|
12,695 |
7,372 |
$71K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
699 |
586 |
$69K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
3,786 |
1,643 |
$69K |
| 82378 |
|
12,993 |
8,534 |
$69K |
| J9045 |
Injection, carboplatin, 50 mg |
2,571 |
1,436 |
$67K |
| 77080 |
|
2,551 |
2,089 |
$67K |
| 88304 |
|
2,122 |
1,731 |
$67K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
967 |
750 |
$66K |
| J9395 |
Injection, fulvestrant, 25 mg |
1,393 |
1,032 |
$65K |
| 81003 |
|
9,518 |
7,385 |
$64K |
| J0475 |
Injection, baclofen, 10 mg |
247 |
208 |
$64K |
| 88185 |
|
2,187 |
1,310 |
$64K |
| 92588 |
|
973 |
918 |
$63K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
624 |
612 |
$63K |
| 72141 |
|
1,098 |
935 |
$61K |
| 20611 |
|
716 |
571 |
$61K |
| 70491 |
|
1,234 |
1,047 |
$59K |
| 76513 |
|
913 |
753 |
$58K |
| 92235 |
|
1,669 |
1,429 |
$58K |
| 76642 |
|
1,749 |
1,529 |
$57K |
| 78306 |
|
897 |
733 |
$57K |
| J9190 |
Injection, fluorouracil, 500 mg |
5,789 |
2,175 |
$56K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
219 |
195 |
$56K |
| 92133 |
|
6,895 |
5,804 |
$56K |
| J9358 |
Injection, fam-trastuzumab deruxtecan-nxki, 1 mg |
76 |
41 |
$56K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
2,057 |
1,630 |
$55K |
| 84443 |
Thyroid stimulating hormone (TSH) |
18,591 |
12,728 |
$55K |
| 85610 |
|
20,710 |
15,280 |
$55K |
| 93970 |
|
1,897 |
1,603 |
$54K |
| 87015 |
|
2,683 |
1,881 |
$54K |
| 72110 |
|
1,610 |
1,374 |
$52K |
| J9022 |
Injection, atezolizumab, 10 mg |
19 |
12 |
$51K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
2,824 |
1,025 |
$51K |
| 84550 |
|
3,787 |
2,081 |
$49K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
903 |
807 |
$47K |
| 82728 |
|
11,985 |
8,475 |
$47K |
| 71045 |
Radiologic examination, chest; single view |
11,109 |
8,709 |
$45K |
| 77065 |
Tomosynthesis, mammo |
1,750 |
1,416 |
$45K |
| 86900 |
|
14,839 |
6,905 |
$44K |
| 76830 |
Ultrasound, transvaginal |
1,126 |
1,028 |
$44K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
10,201 |
8,081 |
$44K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
15 |
14 |
$43K |
| 77012 |
|
275 |
213 |
$43K |
| 92550 |
|
674 |
607 |
$43K |
| C1769 |
Guide wire |
3,647 |
2,676 |
$42K |
| 31615 |
|
91 |
67 |
$41K |
| 70544 |
|
551 |
469 |
$41K |
| 81002 |
|
3,445 |
2,418 |
$41K |
| 85027 |
|
12,937 |
7,614 |
$41K |
| 92060 |
|
1,188 |
1,119 |
$41K |
| J1644 |
Injection, heparin sodium, per 1000 units |
7,892 |
3,379 |
$40K |
| J9267 |
Injection, paclitaxel, 1 mg |
3,207 |
1,227 |
$39K |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
1,066 |
903 |
$39K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
9,332 |
7,667 |
$39K |
| 73030 |
|
1,754 |
1,368 |
$39K |
| 81025 |
|
1,038 |
887 |
$38K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
12,136 |
9,932 |
$38K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
2,340 |
929 |
$38K |
| 86901 |
|
14,664 |
6,858 |
$38K |
| 38222 |
|
188 |
150 |
$37K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
2,322 |
863 |
$37K |
| Q5122 |
Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg |
21 |
14 |
$36K |
| 73564 |
|
1,231 |
966 |
$36K |
| J1442 |
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram |
304 |
64 |
$36K |
| 93017 |
|
1,575 |
1,268 |
$35K |
| 88342 |
|
2,642 |
2,148 |
$35K |
| 96411 |
|
3,958 |
2,288 |
$35K |
| 94010 |
|
1,270 |
1,097 |
$35K |
| 97162 |
|
710 |
600 |
$35K |
| 66821 |
|
459 |
333 |
$35K |
| 81001 |
|
14,369 |
10,688 |
$34K |
| 96377 |
|
2,415 |
1,476 |
$34K |
| 86301 |
|
3,588 |
2,087 |
$34K |
| J9171 |
Injection, docetaxel, 1 mg |
1,618 |
679 |
$34K |
| 85730 |
|
14,718 |
11,139 |
$34K |
| 62370 |
|
283 |
239 |
$33K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
459 |
402 |
$33K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,892 |
2,510 |
$33K |
| J9145 |
Injection, daratumumab, 10 mg |
623 |
171 |
$33K |
| J9041 |
Injection, bortezomib, 0.1 mg |
281 |
61 |
$31K |
| 97535 |
Self-care/home management training, each 15 minutes |
1,490 |
1,028 |
$31K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
8,981 |
6,891 |
$31K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
2,307 |
955 |
$31K |
| 77290 |
|
222 |
174 |
$30K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
123 |
94 |
$30K |
| 78816 |
|
255 |
226 |
$30K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
38,015 |
26,398 |
$29K |
| 76514 |
|
856 |
742 |
$29K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
307 |
162 |
$29K |
| 88341 |
|
1,437 |
1,061 |
$28K |
| 74178 |
|
883 |
731 |
$28K |
| 67113 |
|
73 |
52 |
$28K |
| J9264 |
Injection, paclitaxel protein-bound particles, 1 mg |
418 |
78 |
$28K |
| 87040 |
|
5,594 |
2,496 |
$27K |
| 86300 |
|
7,916 |
4,052 |
$27K |
| 51798 |
|
1,637 |
1,346 |
$27K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
2,805 |
2,404 |
$26K |
| J0485 |
Injection, belatacept, 1 mg |
1,904 |
755 |
$26K |
| J9070 |
Cyclophosphamide, 100 mg |
912 |
469 |
$26K |
| 36592 |
|
2,401 |
1,127 |
$26K |
| 84439 |
|
8,299 |
5,751 |
$26K |
| 73130 |
|
854 |
634 |
$25K |
| 84100 |
|
12,051 |
6,231 |
$25K |
| 73630 |
|
1,596 |
1,256 |
$25K |
| 84484 |
|
9,823 |
6,106 |
$25K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
3,692 |
1,849 |
$25K |
| 77001 |
|
1,919 |
1,541 |
$25K |
| 92025 |
|
1,376 |
1,194 |
$25K |
| 69210 |
|
481 |
444 |
$24K |
| 94726 |
|
1,089 |
917 |
$24K |
| 72100 |
|
1,154 |
992 |
$24K |
| 85007 |
|
7,894 |
4,426 |
$23K |
| Q9956 |
Injection, octafluoropropane microspheres, per ml |
1,247 |
1,019 |
$23K |
| 99201 |
|
255 |
252 |
$23K |
| 70486 |
|
436 |
390 |
$23K |
| 73610 |
|
745 |
616 |
$22K |
| 52000 |
|
89 |
71 |
$22K |
| 94060 |
|
682 |
532 |
$22K |
| 92587 |
|
961 |
927 |
$22K |
| 96368 |
|
2,722 |
1,501 |
$22K |
| 92582 |
|
585 |
562 |
$22K |
| 87077 |
|
5,175 |
3,722 |
$22K |
| 97116 |
|
611 |
272 |
$22K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
1,726 |
1,223 |
$22K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
1,471 |
1,113 |
$21K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
203 |
177 |
$21K |
| 70480 |
|
368 |
332 |
$21K |
| 82784 |
|
12,808 |
5,255 |
$21K |
| 82248 |
|
9,547 |
6,148 |
$21K |
| J1756 |
Injection, iron sucrose, 1 mg |
2,599 |
1,080 |
$21K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
7,001 |
5,274 |
$21K |
| 86923 |
|
4,260 |
1,882 |
$20K |
| 64612 |
|
193 |
145 |
$20K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
62 |
53 |
$20K |
| 93971 |
|
1,055 |
873 |
$20K |
| 87075 |
|
2,862 |
2,097 |
$20K |
| 77295 |
|
63 |
52 |
$19K |
| 92285 |
|
2,603 |
2,131 |
$19K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
135 |
64 |
$19K |
| 77373 |
|
84 |
12 |
$18K |
| 96409 |
|
1,673 |
902 |
$18K |
| 83540 |
|
8,064 |
6,012 |
$18K |
| J3480 |
Injection, potassium chloride, per 2 meq |
1,457 |
556 |
$18K |
| 83550 |
|
7,843 |
5,870 |
$18K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
6,320 |
4,922 |
$18K |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
5,234 |
2,986 |
$18K |
| 72050 |
|
520 |
456 |
$17K |
| 77280 |
|
86 |
61 |
$17K |
| 84156 |
|
1,813 |
1,329 |
$17K |
| 66180 |
|
15 |
13 |
$17K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
478 |
403 |
$17K |
| 72158 |
|
402 |
347 |
$17K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,263 |
1,059 |
$17K |
| 82607 |
|
4,493 |
3,486 |
$17K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
7,239 |
4,138 |
$16K |
| 73502 |
|
922 |
741 |
$16K |
| 83880 |
|
3,635 |
2,814 |
$16K |
| 73110 |
|
405 |
324 |
$15K |
| 19083 |
|
31 |
25 |
$15K |
| 76882 |
|
188 |
163 |
$15K |
| 92604 |
|
842 |
726 |
$15K |
| 84481 |
|
2,235 |
1,404 |
$14K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
44 |
25 |
$14K |
| 72157 |
|
147 |
127 |
$14K |
| 88313 |
|
1,489 |
1,096 |
$14K |
| 86304 |
|
1,854 |
1,251 |
$14K |
| 72156 |
|
208 |
192 |
$14K |
| 92136 |
|
1,269 |
1,065 |
$14K |
| 88360 |
|
817 |
624 |
$14K |
| J1815 |
Injection, insulin, per 5 units |
4,671 |
1,745 |
$13K |
| 74160 |
|
308 |
262 |
$13K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
12,604 |
10,077 |
$13K |
| 85651 |
|
3,691 |
2,976 |
$13K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
3,261 |
2,718 |
$13K |
| 73221 |
|
119 |
108 |
$13K |
| 88112 |
|
650 |
446 |
$13K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
216 |
192 |
$13K |
| 92020 |
|
1,704 |
1,382 |
$12K |
| 88307 |
|
897 |
767 |
$12K |
| 82550 |
|
7,419 |
5,336 |
$12K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
2,217 |
1,380 |
$12K |
| 80061 |
Lipid panel |
7,559 |
5,698 |
$12K |
| 82746 |
|
3,169 |
2,464 |
$12K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
1,138 |
678 |
$11K |
| 87186 |
|
5,223 |
3,624 |
$11K |
| 72131 |
|
571 |
470 |
$11K |
| 92524 |
|
575 |
462 |
$11K |
| 84153 |
|
4,259 |
3,095 |
$11K |
| 81050 |
|
1,227 |
914 |
$11K |
| 67036 |
|
49 |
40 |
$11K |
| 82570 |
|
1,239 |
816 |
$10K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
620 |
402 |
$10K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
4,036 |
3,413 |
$10K |
| J9206 |
Injection, irinotecan, 20 mg |
2,678 |
1,025 |
$10K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
385 |
310 |
$10K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
2,419 |
1,946 |
$10K |
| 87206 |
|
2,085 |
1,161 |
$10K |
| 76937 |
|
1,585 |
1,313 |
$9K |
| 88321 |
|
467 |
395 |
$9K |
| 76942 |
|
503 |
368 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
7,529 |
5,711 |
$9K |
| 82553 |
|
6,047 |
4,442 |
$9K |
| J2060 |
Injection, lorazepam, 2 mg |
1,348 |
895 |
$9K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
91 |
75 |
$9K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
637 |
418 |
$9K |
| 86140 |
|
4,178 |
3,252 |
$9K |
| J9310 |
Injection, rituximab, 100 mg |
41 |
28 |
$9K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
992 |
849 |
$9K |
| 87340 |
|
1,900 |
1,497 |
$9K |
| 73560 |
|
712 |
526 |
$9K |
| 64483 |
|
114 |
92 |
$9K |
| 72082 |
|
299 |
265 |
$8K |
| 73562 |
|
657 |
504 |
$8K |
| 83970 |
|
1,272 |
926 |
$8K |
| 92579 |
|
1,218 |
1,188 |
$8K |
| 83690 |
|
8,289 |
6,038 |
$8K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
378 |
313 |
$8K |
| 70496 |
|
67 |
57 |
$8K |
| 85045 |
|
11,555 |
8,060 |
$8K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
8,392 |
6,529 |
$8K |
| 83883 |
|
3,268 |
2,337 |
$8K |
| 82375 |
|
770 |
594 |
$8K |
| 82105 |
|
1,688 |
1,238 |
$8K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,243 |
1,062 |
$7K |
| 84155 |
|
4,448 |
3,322 |
$7K |
| 88300 |
|
555 |
449 |
$7K |
| 73521 |
|
285 |
232 |
$7K |
| 87205 |
|
3,283 |
2,353 |
$7K |
| J3489 |
Injection, zoledronic acid, 1 mg |
1,704 |
1,307 |
$7K |
| 84132 |
|
560 |
411 |
$7K |
| 84165 |
|
4,515 |
3,335 |
$7K |
| 76881 |
|
144 |
121 |
$7K |
| 84480 |
|
990 |
709 |
$7K |
| 77332 |
|
204 |
160 |
$7K |
| 93975 |
|
379 |
328 |
$7K |
| 72040 |
|
177 |
143 |
$7K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
123 |
110 |
$6K |
| 87799 |
|
3,830 |
1,430 |
$6K |
| 86334 |
|
3,843 |
2,816 |
$6K |
| 84702 |
|
1,441 |
1,176 |
$6K |
| P9047 |
Infusion, albumin (human), 25%, 50 ml |
1,053 |
426 |
$6K |
| 86803 |
|
2,203 |
1,809 |
$6K |
| 84436 |
|
1,593 |
1,089 |
$6K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
5,775 |
4,958 |
$6K |
| C9097 |
Inj, faricimab-svoa, 0.1 mg |
34 |
27 |
$6K |
| 77072 |
|
114 |
114 |
$6K |
| 94664 |
|
2,469 |
1,979 |
$6K |
| 87497 |
|
4,442 |
2,060 |
$6K |
| 97165 |
|
1,545 |
1,253 |
$6K |
| 74150 |
|
44 |
37 |
$6K |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
275 |
162 |
$6K |
| 86704 |
|
1,211 |
994 |
$5K |
| 92556 |
|
117 |
115 |
$5K |
| 83605 |
|
3,834 |
2,672 |
$5K |
| 83020 |
|
2,193 |
2,000 |
$5K |
| 74018 |
|
361 |
298 |
$5K |
| 29581 |
|
365 |
139 |
$5K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,515 |
1,631 |
$5K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
42 |
39 |
$5K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
1,565 |
1,270 |
$5K |
| Q3014 |
Telehealth originating site facility fee |
17,602 |
13,838 |
$5K |
| 84703 |
|
2,018 |
1,754 |
$5K |
| C1788 |
Port, indwelling (implantable) |
216 |
184 |
$5K |
| 88184 |
|
1,878 |
1,327 |
$4K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
3,079 |
1,878 |
$4K |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
275 |
162 |
$4K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
294 |
230 |
$4K |
| 92586 |
|
91 |
81 |
$4K |
| 82150 |
|
3,338 |
1,894 |
$4K |
| 88172 |
|
667 |
483 |
$4K |
| 76377 |
|
373 |
303 |
$4K |
| 94729 |
|
2,017 |
1,704 |
$4K |
| V2785 |
Processing, preserving and transporting corneal tissue |
82 |
68 |
$4K |
| 70482 |
|
13 |
12 |
$4K |
| 0399T |
|
43 |
35 |
$4K |
| 74240 |
|
70 |
63 |
$4K |
| 87449 |
|
3,266 |
1,330 |
$4K |
| 80076 |
|
3,822 |
3,160 |
$4K |
| C8908 |
Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral |
33 |
26 |
$4K |
| 83516 |
|
746 |
355 |
$4K |
| 64642 |
|
29 |
26 |
$3K |
| 93320 |
|
110 |
87 |
$3K |
| 99215 |
Prolong outpt/office vis |
71 |
63 |
$3K |
| 87102 |
|
878 |
638 |
$3K |
| 92132 |
|
435 |
362 |
$3K |
| 93225 |
|
336 |
260 |
$3K |
| 36593 |
|
228 |
173 |
$3K |
| 96376 |
|
1,745 |
1,014 |
$3K |
| 74230 |
|
69 |
52 |
$3K |
| G0268 |
Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing |
152 |
126 |
$3K |
| 88108 |
|
833 |
669 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
4,650 |
3,178 |
$3K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
295 |
226 |
$3K |
| 94618 |
|
370 |
310 |
$3K |
| 76870 |
|
33 |
28 |
$3K |
| 84403 |
|
1,230 |
973 |
$3K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
1,113 |
631 |
$3K |
| 65222 |
|
70 |
64 |
$3K |
| 64643 |
|
26 |
24 |
$2K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
523 |
299 |
$2K |
| 80197 |
|
1,390 |
486 |
$2K |
| 83625 |
|
133 |
87 |
$2K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
673 |
550 |
$2K |
| 36410 |
|
214 |
176 |
$2K |
| 82043 |
|
1,927 |
1,469 |
$2K |
| 87081 |
|
2,008 |
1,591 |
$2K |
| 93880 |
|
125 |
93 |
$2K |
| 92520 |
|
181 |
148 |
$2K |
| 74220 |
|
77 |
66 |
$2K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
297 |
248 |
$2K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,274 |
1,034 |
$2K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
1,218 |
653 |
$2K |
| 93226 |
|
245 |
188 |
$2K |
| C1729 |
Catheter, drainage |
315 |
229 |
$2K |
| 88311 |
|
588 |
446 |
$2K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
1,029 |
895 |
$2K |
| 86902 |
|
538 |
294 |
$2K |
| G0498 |
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion |
642 |
274 |
$2K |
| P9021 |
Red blood cells, each unit |
72 |
44 |
$2K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
2,366 |
999 |
$2K |
| 94660 |
|
31 |
28 |
$2K |
| 86706 |
|
1,131 |
906 |
$2K |
| 82803 |
|
776 |
598 |
$2K |
| 43235 |
|
35 |
27 |
$2K |
| 88312 |
|
14 |
12 |
$1K |
| 80198 |
|
73 |
67 |
$1K |
| 92652 |
|
45 |
37 |
$1K |
| 17311 |
|
37 |
26 |
$1K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
125 |
42 |
$1K |
| 92240 |
|
31 |
27 |
$1K |
| 87533 |
|
1,568 |
845 |
$1K |
| 83050 |
|
772 |
596 |
$1K |
| 94727 |
|
486 |
401 |
$1K |
| J1940 |
Injection, furosemide, up to 20 mg |
1,109 |
598 |
$1K |
| 86769 |
|
26 |
15 |
$1K |
| 82945 |
|
180 |
134 |
$1K |
| 87507 |
|
46 |
39 |
$1K |
| 10060 |
|
14 |
12 |
$1K |
| 72114 |
|
14 |
14 |
$1K |
| 76000 |
|
636 |
511 |
$1K |
| 36600 |
|
414 |
326 |
$1K |
| 82533 |
|
1,293 |
870 |
$1K |
| 86328 |
|
54 |
31 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13 |
13 |
$1K |
| 15770 |
|
28 |
26 |
$1K |
| 72070 |
|
65 |
53 |
$1K |
| 82977 |
|
2,811 |
1,445 |
$1K |
| J7070 |
Infusion, d5w, 1000 cc |
131 |
79 |
$1K |
| 86038 |
|
487 |
388 |
$1K |
| 93356 |
|
1,385 |
1,223 |
$1K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
208 |
168 |
$1K |
| 93325 |
|
140 |
102 |
$1K |
| 82610 |
|
1,852 |
1,053 |
$1K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
540 |
440 |
$1K |
| 73120 |
|
59 |
40 |
$1K |
| 85384 |
|
276 |
205 |
$1K |
| 92597 |
|
68 |
52 |
$1K |
| 76516 |
|
37 |
37 |
$974.83 |
| 77470 |
|
14 |
12 |
$953.13 |
| 82024 |
|
1,135 |
762 |
$880.22 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
1,084 |
936 |
$824.22 |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
15 |
13 |
$797.52 |
| 64493 |
|
32 |
25 |
$772.04 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
410 |
363 |
$744.88 |
| 93296 |
|
48 |
39 |
$736.52 |
| 92526 |
|
16 |
13 |
$677.02 |
| 86703 |
|
147 |
124 |
$667.69 |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
43 |
26 |
$635.43 |
| 92082 |
|
119 |
91 |
$609.72 |
| 83021 |
|
115 |
98 |
$593.35 |
| 72202 |
|
41 |
38 |
$593.18 |
| 85240 |
|
120 |
102 |
$582.02 |
| 72146 |
|
32 |
25 |
$581.78 |
| 86592 |
|
386 |
322 |
$562.78 |
| 93350 |
|
19 |
12 |
$552.19 |
| 73620 |
|
15 |
12 |
$543.28 |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
365 |
311 |
$523.85 |
| 86922 |
|
160 |
67 |
$523.44 |
| L8509 |
Tracheo-esophageal voice prosthesis, inserted by a licensed health care provider, any type |
14 |
12 |
$516.01 |
| 92602 |
|
14 |
14 |
$505.30 |
| 93246 |
|
29 |
26 |
$502.95 |
| 83521 |
|
1,930 |
965 |
$502.71 |
| 92650 |
|
32 |
32 |
$500.01 |
| 95874 |
|
291 |
241 |
$497.20 |
| 80069 |
|
309 |
199 |
$485.44 |
| P3000 |
Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision |
56 |
55 |
$476.07 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
4,078 |
3,400 |
$472.37 |
| 20553 |
|
65 |
55 |
$462.02 |
| 36590 |
|
16 |
12 |
$461.56 |
| 82232 |
|
451 |
336 |
$454.39 |
| 80377 |
|
28 |
28 |
$437.96 |
| 64447 |
|
15 |
13 |
$420.43 |
| 83001 |
|
51 |
39 |
$391.08 |
| 10022 |
|
20 |
13 |
$384.09 |
| 80320 |
|
132 |
99 |
$382.36 |
| 20605 |
|
21 |
13 |
$380.73 |
| C1758 |
Catheter, ureteral |
42 |
30 |
$361.80 |
| 82670 |
|
59 |
50 |
$348.05 |
| 86708 |
|
121 |
103 |
$345.14 |
| J3300 |
Injection, triamcinolone acetonide, preservative free, 1 mg |
82 |
57 |
$341.75 |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
53 |
49 |
$341.71 |
| 75572 |
|
14 |
12 |
$340.16 |
| 86403 |
|
21 |
15 |
$333.11 |
| 70498 |
|
15 |
12 |
$332.48 |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
43 |
26 |
$322.99 |
| 85230 |
|
13 |
12 |
$314.56 |
| C1726 |
Catheter, balloon dilatation, non-vascular |
47 |
38 |
$309.24 |
| 86606 |
|
200 |
70 |
$301.87 |
| 87516 |
|
89 |
63 |
$294.55 |
| 81015 |
|
263 |
198 |
$281.87 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
66 |
54 |
$272.54 |
| 89051 |
|
119 |
88 |
$266.52 |
| 87305 |
|
391 |
232 |
$256.94 |
| 86235 |
|
74 |
36 |
$255.65 |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
17 |
15 |
$245.96 |
| J2785 |
Injection, regadenoson, 0.1 mg |
474 |
385 |
$236.61 |
| 86880 |
|
119 |
76 |
$235.88 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
395 |
331 |
$220.54 |
| 85014 |
|
260 |
195 |
$216.43 |
| 82664 |
|
13 |
13 |
$203.97 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
57 |
30 |
$198.12 |
| 83520 |
|
36 |
24 |
$191.02 |
| 87116 |
|
399 |
291 |
$187.17 |
| 85378 |
|
669 |
519 |
$175.18 |
| 77003 |
|
14 |
13 |
$169.40 |
| 86480 |
|
138 |
109 |
$166.77 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
69 |
58 |
$165.39 |
| 90715 |
|
307 |
262 |
$165.05 |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
17 |
14 |
$157.05 |
| 84311 |
|
182 |
127 |
$138.18 |
| 86357 |
|
14 |
13 |
$134.81 |
| 86255 |
|
27 |
24 |
$123.92 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
66 |
42 |
$114.33 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
65 |
42 |
$114.33 |
| 80074 |
|
129 |
106 |
$113.85 |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
39 |
25 |
$109.56 |
| 86431 |
|
82 |
42 |
$106.82 |
| Q0247 |
Injection, sotrovimab, 500 mg |
20 |
19 |
$104.48 |
| J7325 |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg |
18 |
13 |
$102.44 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
86 |
75 |
$100.44 |
| 36591 |
|
44 |
29 |
$95.97 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
779 |
668 |
$94.25 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
14 |
14 |
$94.02 |
| 86225 |
|
39 |
37 |
$89.92 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
17 |
13 |
$86.05 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
17 |
13 |
$86.05 |
| 92226 |
|
15 |
13 |
$73.62 |
| 82330 |
|
178 |
87 |
$70.86 |
| 89050 |
|
31 |
25 |
$67.67 |
| 83986 |
|
95 |
84 |
$55.11 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
319 |
233 |
$51.43 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
882 |
681 |
$47.93 |
| 99153 |
Mod sedat endo service >5yrs |
44 |
37 |
$45.83 |
| 83002 |
|
50 |
39 |
$42.05 |
| 86777 |
|
18 |
13 |
$38.50 |
| 84402 |
|
30 |
24 |
$37.87 |
| 84146 |
|
30 |
26 |
$24.30 |
| 84154 |
|
220 |
170 |
$24.11 |
| 86355 |
|
15 |
14 |
$23.28 |
| 86360 |
|
13 |
13 |
$23.28 |
| 86359 |
|
15 |
14 |
$23.28 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
315 |
203 |
$22.43 |
| 87535 |
|
17 |
12 |
$22.06 |
| 77387 |
|
266 |
40 |
$19.68 |
| 99152 |
|
31 |
27 |
$19.35 |
| 83010 |
|
47 |
36 |
$17.58 |
| 84145 |
|
151 |
105 |
$17.17 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
26 |
13 |
$15.63 |
| 82530 |
|
222 |
144 |
$6.75 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
25 |
21 |
$4.79 |
| 85660 |
|
18 |
12 |
$3.96 |
| 84479 |
|
16 |
13 |
$3.84 |
| 77002 |
|
17 |
13 |
$0.51 |
| 87556 |
|
18 |
12 |
$0.00 |
| 86870 |
|
57 |
25 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
61 |
43 |
$0.00 |
| J1741 |
Injection, ibuprofen, 100 mg |
245 |
224 |
$0.00 |
| 97802 |
|
103 |
87 |
$0.00 |
| 92700 |
|
48 |
44 |
$0.00 |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
112 |
53 |
$0.00 |
| 85018 |
|
16 |
15 |
$0.00 |
| 90686 |
|
15 |
12 |
$0.00 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
48 |
25 |
$0.00 |
| 94200 |
|
16 |
12 |
$0.00 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
57 |
50 |
$0.00 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
13 |
12 |
$0.00 |
| 64494 |
|
16 |
14 |
$0.00 |
| 88377 |
|
22 |
14 |
$0.00 |
| 10006 |
|
14 |
13 |
$0.00 |
| 86945 |
|
17 |
12 |
$0.00 |
| 73720 |
|
17 |
13 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
13 |
12 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
15 |
14 |
$0.00 |
| J9370 |
Vincristine sulfate, 1 mg |
306 |
184 |
$0.00 |
| 90682 |
|
28 |
25 |
$0.00 |
| 88237 |
|
18 |
13 |
$0.00 |
| J1956 |
Injection, levofloxacin, 250 mg |
146 |
85 |
$0.00 |
| 99499 |
|
140 |
130 |
$0.00 |
| J9260 |
Injection, methotrexate sodium, 50 mg |
114 |
64 |
$0.00 |
| 88365 |
|
31 |
24 |
$0.00 |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
313 |
155 |
$0.00 |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
12 |
12 |
$0.00 |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
47 |
27 |
$0.00 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
115 |
79 |
$0.00 |
| 86787 |
|
17 |
12 |
$0.00 |
| 92585 |
|
12 |
12 |
$0.00 |
| J1738 |
Injection, meloxicam, 1 mg |
13 |
12 |
$0.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
13 |
13 |
$0.00 |
| 87101 |
|
13 |
12 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
33 |
13 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
13 |
12 |
$0.00 |
| 01999 |
|
26 |
24 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
13 |
12 |
$0.00 |
| 82652 |
|
13 |
12 |
$0.00 |